摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-Morpholin-4-ylcyclohex-3-en-1-yl)phenol | 1333477-94-3

中文名称
——
中文别名
——
英文名称
4-(4-Morpholin-4-ylcyclohex-3-en-1-yl)phenol
英文别名
——
4-(4-Morpholin-4-ylcyclohex-3-en-1-yl)phenol化学式
CAS
1333477-94-3
化学式
C16H21NO2
mdl
——
分子量
259.348
InChiKey
UJSXVVKLVJSYBS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    32.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    4-(4-Morpholin-4-ylcyclohex-3-en-1-yl)phenol 在 sodium tetrahydroborate 、 sodium hydroxide 、 盐酸 作用下, 以 甲醇1,2-二氯乙烷 为溶剂, 生成
    参考文献:
    名称:
    Novel and highly potent histamine H3 receptor ligands. Part 2: Exploring the cyclohexylamine-based series
    摘要:
    Synthesis and biological evaluation of novel and potent cyclohexylamine-based histamine H3 receptor inverse agonists are described. Compounds in this newly identified series exhibited subnanomolar binding affinities for human receptor and no significant interaction with hERG channel. One derivative (10t) demonstrated enhanced in vivo efficiency and preferential brain distribution, both properties suitable for potential clinical evaluation. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.06.102
  • 作为产物:
    描述:
    吗啉4-(4-羟基苯基)环己酮 在 APTS 作用下, 以 甲苯 为溶剂, 反应 10.0h, 生成 4-(4-Morpholin-4-ylcyclohex-3-en-1-yl)phenol
    参考文献:
    名称:
    Novel and highly potent histamine H3 receptor ligands. Part 2: Exploring the cyclohexylamine-based series
    摘要:
    Synthesis and biological evaluation of novel and potent cyclohexylamine-based histamine H3 receptor inverse agonists are described. Compounds in this newly identified series exhibited subnanomolar binding affinities for human receptor and no significant interaction with hERG channel. One derivative (10t) demonstrated enhanced in vivo efficiency and preferential brain distribution, both properties suitable for potential clinical evaluation. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.06.102
点击查看最新优质反应信息

文献信息

  • Trans-Dekalincarbonitrile
    申请人:MERCK PATENT GmbH
    公开号:EP0127816B1
    公开(公告)日:1987-08-19
查看更多